Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Journal of Clinical Psychopharmacology
|
October 21, 2020
Identification of Optimal Measures of Human Abuse Potential: A Post Hoc Assessment of 19 Studies
Megan J Shram, Naama Levy-Cooperman, Sian Ratcliffe, et al.
Journal of Clinical Pharmacology
|
November 27, 2018
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study
Sanjeev Pathak, Bradley Vince, Debra Kelsh, et al.
Current Medical Research and Opinion
|
May 16, 2022
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate
Megan J Shram, Beatrice Setnik, Lynn Webster, et al.
Pain
|
May 21, 2015
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment
Richard L Rauck, Martin E Hale, Almasa Bass, et al.
Journal of Clinical Psychopharmacology
|
March 16, 2026
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom
Chad J Reissig, Ling Chen, Srikanth C Nallani, et al.
The Journal of Pain
|
May 9, 2017
Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations
Shannon M Smith, Judith K Jones, Nathaniel P Katz, et al.
Pain
|
October 24, 2013
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations
Alec B O'Connor, Dennis C Turk, Robert H Dworkin, et al.
Pain
|
September 25, 2012
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations
Sandra D Comer, James P Zacny, Robert H Dworkin, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Journal of Clinical Psychopharmacology
|
October 21, 2020
Identification of Optimal Measures of Human Abuse Potential: A Post Hoc Assessment of 19 Studies
Megan J Shram, Naama Levy-Cooperman, Sian Ratcliffe, et al.
Journal of Clinical Pharmacology
|
November 27, 2018
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study
Sanjeev Pathak, Bradley Vince, Debra Kelsh, et al.
Current Medical Research and Opinion
|
May 16, 2022
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate
Megan J Shram, Beatrice Setnik, Lynn Webster, et al.
Pain
|
May 21, 2015
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment
Richard L Rauck, Martin E Hale, Almasa Bass, et al.
Journal of Clinical Psychopharmacology
|
March 16, 2026
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom
Chad J Reissig, Ling Chen, Srikanth C Nallani, et al.
The Journal of Pain
|
May 9, 2017
Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations
Shannon M Smith, Judith K Jones, Nathaniel P Katz, et al.
Pain
|
October 24, 2013
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations
Alec B O'Connor, Dennis C Turk, Robert H Dworkin, et al.
Pain
|
September 25, 2012
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations
Sandra D Comer, James P Zacny, Robert H Dworkin, et al.
Page
of 5